09:13 AM EDT, 08/13/2025 (MT Newswires) -- Vor Biopharma ( VOR ) shares were up more than 36% in Wednesday premarket trading after the company said its collaborator RemeGen has achieved the primary endpoint in a phase 3 clinical study in China evaluating telitacicept in adults with primary Sjogren's disease.

The study achieved the primary endpoint of improving disease activity measured by a reduction in EULAR Sjogren's syndrome disease activity index, with telitacicept demonstrating a favorable safety profile, Vor Biopharma ( VOR ) said.

In June, Vor Biopharma ( VOR ) was granted global rights (excluding China, Hong Kong, Macau and Taiwan) to develop and commercialize telitacicept under an exclusive license agreement with RemeGen.

RemeGen plans to submit a biologics license application to the National Medical Products Administration in China for primary Sjogren's disease, which would be telitacicept's fourth approved indication in China, Vor Biopharma ( VOR ) said.